COMPARE · Data as of August 28, 2026
MPT vs SBRA
Verdict: Side-by-side breakdown using the Bull Rankings model. MPT scored 67.0, SBRA scored 71.0 — SBRA leads.
Compare another set
Different reporting periods. SBRA's fundamentals are as of June 2026, but MPT's are as of March 2026 — a 3-month gap. Growth, margin and valuation figures below therefore describe different windows and aren't strictly like-for-like.
MPT
Medical Properties Trust, Inc.
69Fin
$4.09 · $2.4B
fundamentals as of
Strength gap
3.9
MPT leads
SBRA
Sabra Health Care REIT, Inc.
65.1Fin
$20.70 · $5.3B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Fastest growthSBRA+10.2%
- Strongest balance sheetSBRA0.96
Side by side · every name on one set of axes
Fundamentals, head-to-head
MPT
SBRA
8.8%A-
Yield
5.8%A-
-2.4%D+
Rev
+10.2%B
2.16C
D/E
0.96B
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
The companies
MPTMedical Properties Trust, Inc.
Why now
REIT - Healthcare Facilities · market cap $2.4b. Down 37% from 52-week high of $6.47 — deep drawdown territory. 7 sell-side analysts rate this a Hold with a mean 1-yr target of $5.11 (implying +25% upside).
Moat
Turnaround / out-of-favor name — GAAP-unprofitable for now, so the durability case is forward-looking: it rests on a recovery (margin normalization, a cyclical upturn or restructuring) or an un-monetized asset (IP / network effects / first-mover position) rather than on current reported results.
Risk
D/E 2.16 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Currently unprofitable (margin -2.7%) — path to GAAP profitability is the core thesis risk. Down 37% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
SBRASabra Health Care REIT, Inc.
Why now
REIT - Healthcare Facilities · market cap $5.3b. 9% off the 52-week high of $22.77. Revenue growing +10%, comfortably above the S&P median. 14 sell-side analysts rate this a Buy with a mean 1-yr target of $22.57 (implying +9% upside).
Moat
Moat signals from the quantitative card are modest — profitability and capital efficiency are middle-of-pack. The thesis here depends on softer factors (switching costs, brand, distribution, regulatory protection) not captured by the quality-growth screen.
Risk
Dividend payout 462% of earnings on a 5.8% yield — distribution coverage is thin; one earnings stumble could force a dividend cut. ROE 2% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.